These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36209235)

  • 41. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial.
    Moriarty AS; Louwagie GM; Mdege ND; Morojele N; Tumbo J; Omole OB; Bachmann MO; Kanaan M; Turner A; Parrott S; Siddiqi K; Ayo-Yusuf OA
    Trials; 2019 Jul; 20(1):457. PubMed ID: 31349850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of community active case-finding strategies for detection of tuberculosis in Cambodia: study protocol for a pragmatic cluster randomized controlled trial.
    Teo AKJ; Prem K; Evdokimov K; Ork C; Eng S; Tuot S; Chry M; Mao TE; Hsu LY; Yi S
    Trials; 2020 Feb; 21(1):220. PubMed ID: 32093778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis.
    Verboven L; Callens S; Black J; Maartens G; Dooley KE; Potgieter S; Cartuyvels R; ; Laukens K; Warren RM; Van Rie A
    Res Sq; 2023 Feb; ():. PubMed ID: 36824956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting.
    Chiang TY; Fan SY; Jou R
    PLoS One; 2018; 13(7):e0200755. PubMed ID: 30011319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    De Vos E; Scott L; Voss De Lima Y; Warren RM; Stevens W; Hayes C; da Silva P; Van Rie A
    Int J Tuberc Lung Dis; 2021 Feb; 25(2):134-141. PubMed ID: 33656425
    [No Abstract]   [Full Text] [Related]  

  • 53. Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol.
    Naidoo K; Gengiah S; Yende-Zuma N; Padayatchi N; Barker P; Nunn A; Subrayen P; Abdool Karim SS
    Implement Sci; 2017 Nov; 12(1):129. PubMed ID: 29132380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda.
    Kasozi S; Kirirabwa NS; Kimuli D; Luwaga H; Kizito E; Turyahabwe S; Lukoye D; Byaruhanga R; Chen L; Suarez P
    PLoS One; 2020; 15(12):e0244451. PubMed ID: 33373997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.
    Dickson L; Le Roux SR; Mitrani L; Hill J; Jassat W; Cox H; Mlisana K; Black J; Loveday M; Grant A; Kielmann K; Ndjeka N; Moshabela M; Nicol M
    BMJ Open; 2023 Nov; 13(11):e067121. PubMed ID: 37977868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis.
    Goodall RL; Sanders K; Bronson G; Gurumurthy M; Torrea G; Meredith S; Nunn A; Rusen ID;
    Trials; 2022 Jun; 23(1):474. PubMed ID: 35672833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes in Uganda (CFL-TB): a protocol for a randomized controlled trial.
    Byonanebye DM; Mackline H; Sekaggya-Wiltshire C; Kiragga AN; Lamorde M; Oseku E; King R; Parkes-Ratanshi R
    Trials; 2021 Jun; 22(1):391. PubMed ID: 34120649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
    Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.